These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35303463)

  • 21. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria.
    Oladimeji O; Isaakidis P; Obasanya OJ; Eltayeb O; Khogali M; Van den Bergh R; Kumar AM; Hinderaker SG; Abdurrahman ST; Lawson L; Cuevas LE
    PLoS One; 2014; 9(4):e94393. PubMed ID: 24722139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design.
    Santos AP; Benace CJ; de Medeiros Leung JA; Kritski AL; de Queiroz Mello FC
    BMC Infect Dis; 2024 Oct; 24(1):1112. PubMed ID: 39375590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.
    Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S
    BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study.
    Wrohan I; Nguyen TA; Nguyen VN; Nguyen BH; Hoang TTT; Nguyen PC; Velen K; Marks GB; Fox GJ
    BMC Infect Dis; 2022 Jan; 22(1):68. PubMed ID: 35057754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study.
    Hirpa S; Medhin G; Girma B; Melese M; Mekonen A; Suarez P; Ameni G
    BMC Public Health; 2013 Aug; 13():782. PubMed ID: 23981845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.
    Satti H; McLaughlin MM; Omotayo DB; Keshavjee S; Becerra MC; Mukherjee JS; Seung KJ
    PLoS One; 2012; 7(5):e37114. PubMed ID: 22629356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: a retrospective record review.
    Atif M; Ahmad W; Ahmad N; Malik I; Sarwar S
    Trans R Soc Trop Med Hyg; 2020 Oct; 114(10):733-741. PubMed ID: 32556195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity.
    Geiger K; Patil A; Budhathoki C; Dooley KE; Lowensen K; Ndjeka N; Ngozo J; Farley JE
    J Acquir Immune Defic Syndr; 2023 Nov; 94(3):253-261. PubMed ID: 37757847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
    Ahuja SD; Ashkin D; Avendano M; Banerjee R; Bauer M; Bayona JN; Becerra MC; Benedetti A; Burgos M; Centis R; Chan ED; Chiang CY; Cox H; D'Ambrosio L; DeRiemer K; Dung NH; Enarson D; Falzon D; Flanagan K; Flood J; Garcia-Garcia ML; Gandhi N; Granich RM; Hollm-Delgado MG; Holtz TH; Iseman MD; Jarlsberg LG; Keshavjee S; Kim HR; Koh WJ; Lancaster J; Lange C; de Lange WC; Leimane V; Leung CC; Li J; Menzies D; Migliori GB; Mishustin SP; Mitnick CD; Narita M; O'Riordan P; Pai M; Palmero D; Park SK; Pasvol G; Peña J; Pérez-Guzmán C; Quelapio MI; Ponce-de-Leon A; Riekstina V; Robert J; Royce S; Schaaf HS; Seung KJ; Shah L; Shim TS; Shin SS; Shiraishi Y; Sifuentes-Osornio J; Sotgiu G; Strand MJ; Tabarsi P; Tupasi TE; van Altena R; Van der Walt M; Van der Werf TS; Vargas MH; Viiklepp P; Westenhouse J; Yew WW; Yim JJ;
    PLoS Med; 2012; 9(8):e1001300. PubMed ID: 22952439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ethnic disparities on the treatment outcomes of HIV-negative drug-resistant tuberculosis patients in Kuala Lumpur, Malaysia: A call for a culturally-sensitive community intervention approach.
    Shariff NM; Shah SA; Kamaludin F
    J Glob Antimicrob Resist; 2019 Dec; 19():274-279. PubMed ID: 31100500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
    Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA
    Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.
    Iradukunda A; Ndayishimiye GP; Sinarinzi D; Odjidja EN; Ntakaburimvo N; Nshimirimana I; Izere C
    BMC Public Health; 2021 Nov; 21(1):2142. PubMed ID: 34814876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.